New Immune-Guiding drug takes on stubborn arthritis

NCT ID NCT06946199

Recruiting now Disease control Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial is testing a new drug called cizutamig in 28 people with severe rheumatoid arthritis that hasn't responded to other treatments. The drug works by directing the immune system to attack certain cells involved in the disease. The main goal is to check safety, but researchers will also look for signs that the drug might help control arthritis.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: cizutamig (a drug that directs immune cells to attack certain cells involved in rheumatoid arthritis)
What this could lead to: If it works, this could point toward a new treatment option for people with hard-to-treat rheumatoid arthritis.
What could go wrong: This is a very early, small Phase 1 trial focused on safety, not proof of effectiveness. The drug may cause side effects or fail to improve arthritis symptoms.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RHEUMATOID ARTHRITIS (RA) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

rheumatoid arthritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RHEUMATOID ARTHRITIS (RA)

Contacts and locations

Locations

Wuhan Union Hospital
RECRUITING

Wuhan, Hubei, 430000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.